190 related articles for article (PubMed ID: 28825423)
41. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia.
Girgis RR; Van Snellenberg JX; Glass A; Kegeles LS; Thompson JL; Wall M; Cho RY; Carter CS; Slifstein M; Abi-Dargham A; Lieberman JA
J Psychopharmacol; 2016 May; 30(5):428-35. PubMed ID: 26966119
[TBL] [Abstract][Full Text] [Related]
42. Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance, sedation and patient satisfaction in patients with schizophrenia: a randomised, double-blind, crossover study (eXtRa).
Riedel M; Schmitz M; Østergaard PK; Ferrannini L; Franco MA; Alfano V; Vansvik ED
Schizophr Res; 2015 Mar; 162(1-3):162-8. PubMed ID: 25592805
[TBL] [Abstract][Full Text] [Related]
43. Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.
Walling D; Marder SR; Kane J; Fleischhacker WW; Keefe RS; Hosford DA; Dvergsten C; Segreti AC; Beaver JS; Toler SM; Jett JE; Dunbar GC
Schizophr Bull; 2016 Mar; 42(2):335-43. PubMed ID: 26071208
[TBL] [Abstract][Full Text] [Related]
44. A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.
Lieberman JA; Dunbar G; Segreti AC; Girgis RR; Seoane F; Beaver JS; Duan N; Hosford DA
Neuropsychopharmacology; 2013 May; 38(6):968-75. PubMed ID: 23303043
[TBL] [Abstract][Full Text] [Related]
45. Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia.
Barak S; Arad M; De Levie A; Black MD; Griebel G; Weiner I
Neuropsychopharmacology; 2009 Jun; 34(7):1753-63. PubMed ID: 19158670
[TBL] [Abstract][Full Text] [Related]
46. DMXB (GTS-21) ameliorates the cognitive deficits in beta amyloid(25-35(-) ) injected mice through preventing the dysfunction of alpha7 nicotinic receptor.
Chen L; Wang H; Zhang Z; Li Z; He D; Sokabe M; Chen L
J Neurosci Res; 2010 Jun; 88(8):1784-94. PubMed ID: 20127813
[TBL] [Abstract][Full Text] [Related]
47. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.
Feuerbach D; Pezous N; Weiss M; Shakeri-Nejad K; Lingenhoehl K; Hoyer D; Hurth K; Bilbe G; Pryce CR; McAllister K; Chaperon F; Kucher K; Johns D; Blaettler T; Lopez Lopez C
Br J Pharmacol; 2015 Mar; 172(5):1292-304. PubMed ID: 25363835
[TBL] [Abstract][Full Text] [Related]
48. Prediction of plasma concentration of GTS-21 in hairless rats following monolithic transdermal delivery.
Kawamata H; Tojo K
Biol Pharm Bull; 2002 Mar; 25(3):342-5. PubMed ID: 11913530
[TBL] [Abstract][Full Text] [Related]
49. Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.
Olincy A; Stevens KE
Biochem Pharmacol; 2007 Oct; 74(8):1192-201. PubMed ID: 17714692
[TBL] [Abstract][Full Text] [Related]
50. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.
Roncarati R; Scali C; Comery TA; Grauer SM; Aschmi S; Bothmann H; Jow B; Kowal D; Gianfriddo M; Kelley C; Zanelli U; Ghiron C; Haydar S; Dunlop J; Terstappen GC
J Pharmacol Exp Ther; 2009 May; 329(2):459-68. PubMed ID: 19223665
[TBL] [Abstract][Full Text] [Related]
51. Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia.
Velligan D; Brenner R; Sicuro F; Walling D; Riesenberg R; Sfera A; Merideth C; Sweitzer D; Jaeger J
Schizophr Res; 2012 Jan; 134(1):59-64. PubMed ID: 22088556
[TBL] [Abstract][Full Text] [Related]
52. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
Buchanan RW; Keefe RS; Lieberman JA; Barch DM; Csernansky JG; Goff DC; Gold JM; Green MF; Jarskog LF; Javitt DC; Kimhy D; Kraus MS; McEvoy JP; Mesholam-Gately RI; Seidman LJ; Ball MP; McMahon RP; Kern RS; Robinson J; Marder SR
Biol Psychiatry; 2011 Mar; 69(5):442-9. PubMed ID: 21145041
[TBL] [Abstract][Full Text] [Related]
53. Brief Report: Initial Trial of Alpha7-Nicotinic Receptor Stimulation in Two Adult Patients with Autism Spectrum Disorder.
Olincy A; Blakeley-Smith A; Johnson L; Kem WR; Freedman R
J Autism Dev Disord; 2016 Dec; 46(12):3812-3817. PubMed ID: 27565651
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics and urinary excretion of DMXBA (GTS-21), a compound enhancing cognition.
Mahnir V; Lin B; Prokai-Tatrai K; Kem WR
Biopharm Drug Dispos; 1998 Apr; 19(3):147-51. PubMed ID: 9569996
[TBL] [Abstract][Full Text] [Related]
55. Combining CDP-choline and galantamine, an optimized α7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
Int J Psychophysiol; 2019 Nov; 145():70-82. PubMed ID: 30790597
[TBL] [Abstract][Full Text] [Related]
56. Effects of the α7 nicotinic acetylcholine receptor agonist GTS-21 on the innate immune response in humans.
Kox M; Pompe JC; Gordinou de Gouberville MC; van der Hoeven JG; Hoedemaekers CW; Pickkers P
Shock; 2011 Jul; 36(1):5-11. PubMed ID: 21368716
[TBL] [Abstract][Full Text] [Related]
57. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
Lindenmayer JP; Khan A
Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275
[TBL] [Abstract][Full Text] [Related]
58. The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia.
Bristow LJ; Easton AE; Li YW; Sivarao DV; Lidge R; Jones KM; Post-Munson D; Daly C; Lodge NJ; Gallagher L; Molski T; Pieschl R; Chen P; Hendricson A; Westphal R; Cook J; Iwuagwu C; Morgan D; Benitex Y; King D; Macor JE; Zaczek R; Olson R
PLoS One; 2016; 11(7):e0159996. PubMed ID: 27467081
[TBL] [Abstract][Full Text] [Related]
59. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.
Wishka DG; Walker DP; Yates KM; Reitz SC; Jia S; Myers JK; Olson KL; Jacobsen EJ; Wolfe ML; Groppi VE; Hanchar AJ; Thornburgh BA; Cortes-Burgos LA; Wong EH; Staton BA; Raub TJ; Higdon NR; Wall TM; Hurst RS; Walters RR; Hoffmann WE; Hajos M; Franklin S; Carey G; Gold LH; Cook KK; Sands SB; Zhao SX; Soglia JR; Kalgutkar AS; Arneric SP; Rogers BN
J Med Chem; 2006 Jul; 49(14):4425-36. PubMed ID: 16821801
[TBL] [Abstract][Full Text] [Related]
60. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats.
Hajós M; Hurst RS; Hoffmann WE; Krause M; Wall TM; Higdon NR; Groppi VE
J Pharmacol Exp Ther; 2005 Mar; 312(3):1213-22. PubMed ID: 15523001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
